GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » Total Equity

Kolon TissueGene (XKRX:950160) Total Equity : ₩148,868 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene Total Equity?

Kolon TissueGene's total equity for the quarter that ended in Sep. 2024 was ₩148,868 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Kolon TissueGene Total Equity Historical Data

The historical data trend for Kolon TissueGene's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene Total Equity Chart

Kolon TissueGene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial 92,164.04 48,108.27 38,647.73 91,488.73 114,963.38

Kolon TissueGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123,958.33 114,963.38 116,359.02 162,752.37 148,868.30

Kolon TissueGene Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Kolon TissueGene's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=134910.381-19947.001
=114,963

Kolon TissueGene's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=192872.644-44004.341
=148,868

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon TissueGene Total Equity Related Terms

Thank you for viewing the detailed overview of Kolon TissueGene's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon TissueGene Business Description

Traded in Other Exchanges
N/A
Address
9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850
Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines